The Asia Pacific Inflammatory Bowel Disease Treatment Market would witness market growth of 9.9% CAGR during the forecast period (2021-2027).
Inflammatory bowel disease refers to the medical indication that is responsible to cause chronic inflammation in the gastrointestinal tract. This disease includes Crohn’s disease and Ulcerative colitis. The ulcerative colitis majorly attacks the large intestine and anus. Moreover, it also causes inflammation of sores in the inner lining of the rectum and colon. On the other hand, Crohn’s disease can attack any part of the gastrointestinal tract and any layer of gastrointestinal walls. The prevalence of ulcerative colitis is witnessed more in comparison to Crohn’s disease. Further, the effect of inflammatory bowel disease is witnessed equally on women as well as men and the incidence & prevalence rates are higher in well-established nations as compared to under-developed nations or emerging nations.
The combination of various factors responsible to cause inflammatory bowel disease are genetic factors, autoimmune disorders, and unhealthy lifestyles like sedentary lifestyle, lack of exercise, and smoking. Though, persistent diarrhea, occasional rectal bleeding, and severe abdominal pain & cramps are some of the major symptoms of inflammatory bowel disease. Inflammatory bowel disease is a lifelong disease that requires continuous treatment and management. The medications majorly used to slow the progress of inflammatory bowel disease are immunomodulators, aminosalicylates, corticosteroids, and biologic drugs like TNF inhibitors. Sometimes, antibiotic drugs are also recommended to control the progress of the disease.
The inflammatory bowel disease treatment market is displaying a significant growth in Asia-Pacific. The factors contributing to the growth of the market are growing access to healthcare, increasing per capita medical expenditure, and a rise in the number of patients with inflammatory bowel disease. Additionally, the prevalence of inflammatory bowel disease is higher in several nations in this region like Australia, India, New Zealand, and China.
Moreover, nations in this region are rapidly developing due to which, the eating habits of people residing in such nations are also changing. The changing eating habits have given rise to various health problems and diseases. Moreover, China is known to be the hub of various industries. The advent of new technologies in this region has made people lazy, which has resulted in obesity and thus, has given rise to inflammatory bowel disease. Hence, these factors are likely to escalate the growth of the regional inflammatory bowel disease treatment market in the upcoming period.
The China market dominated the Asia Pacific Oral Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $530.5 million by 2027. The Japan market showcasing a CAGR of 11.3% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 13% during (2021 - 2027).
Based on Type, the market is segmented into Crohn's Disease and Ulcerative Colitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Drug Class, the market is segmented into TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Inflammatory Bowel Disease Treatment Market is Projected to reach USD 29.2 Billion by 2027, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.
By Type
By Distribution Channel
By Route of Administration
By Drug Class
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 